Clinical Pharmacokinetics of Levodopa in Parkinson’s Disease

No abstract is available for this paper.

• Publication year

  1976

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-197601050-00001PMID 797502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interactions Between Levodopa and Other Drugs: Significance in the Treatment of Parkinson’s Disease

  2012cited by this paper
• Levodopa: A Review of its Pharmacological Properties and Therapeutic Uses with Particular Reference to Parkinsonism

  2012cited by this paper
• L-dopa level in plasma, primary condition for the kinetic effect

  2005cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

  1976cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Effects of L-dopa metabolites at a dopamine receptor suggest a basis for ‘on-off’ effect in Parkinson's disease

  1975cited by this paper
• Protein intake and treatment of Parkinson's disease with levodopa.

  1975cited by this paper
• [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].

  1975cited by this paper
• Dopaminergic supersensitivity in the striatum.

  1975cited by this paper
• Letter: Diphasic dyskinesia during levodopa therapy.

  1975cited by this paper
• [Side-effects of L-dopa therapy].

  1975cited by this paper
• DIPHASIC DYSKINESIA DURING LEVODOPA THERAPY

  1975cited by this paper
• Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.

  1975cited by this paper
• Patterns of clinical response and plasma dopa levels in Parkinson's disease

  1975cited by this paper
• Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

  1975cited by this paper
• The effect of probenecid on catecholamine metabolites in human cerebrospinal fluid analyzed by mass fragmentography.

  1975cited by this paper
• Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.

  1975cited by this paper
• On‐off response

  1975cited by this paper
• Effect of chronic levodopa treatment on pyridoxine metabolism

  1975cited by this paper
• Acute overdose with levodopa

  1975cited by this paper
• Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson's disease

  1975cited by this paper
• Parkinson's disease and its chemotherapy.

  1975cited by this paper
• Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease

  1975cited by this paper
• The pharmacokinetic basis of therapeutics with special reference to drugs used in neurology.

  1975cited by this paper
• Human growth hormone response to levodopa. Relation to menopause, depression, and plasma dopa concentration.

  1975cited by this paper
• Interactions of levodopa with inhibitors of monoamine oxidase and L‐aromatic amino acid decarboxylase

  1975cited by this paper
• Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.

  1975cited by this paper
• Treatment of "on-off effect" with a dopa decarboxylase inhibitor.

  1975cited by this paper
• CSF homovanillic acid: an index of dopaminergic activity.

  1975cited by this paper
• Drugs Five Years Later: Levodopa

  1975cited by this paper
• Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.

  1975cited by this paper
• Origins of catecholamine metabolites in monkey cerebrospinal fluid

  1975cited by this paper
• The "on-off" effect.

  1974cited by this paper
• Short- and long-term approaches to the "on-off" phenomenon.

  1974cited by this paper
• Glucose-6-phosphate dehydrogenase slow variant with deficiency in a Spanish family. Relationship with the Gd (minus) Seattle variant.

  1974cited by this paper
• The "on-off" response to chronic L-DOPA treatment of Parkinsonism.

  1974cited by this paper
• Variations in the "on-off" phenomenon.

  1974cited by this paper
• Plasma levodopa and the "on-off" effect.

  1974cited by this paper
• The clinical physiology of side effects in long-term L-DOPA therapy.

  1974cited by this paper
• The mechanisms of action of L-dopa in Parkinson's disease.

  1974cited by this paper
• Dopa, 3‐0‐methyldopa, and metabolites in urine during oral l‐3‐0‐methyldopa therapy

  1974cited by this paper
• The "on-off" side effect of L-DOPA.

  1974cited by this paper
• Metoclopramide, gastric emptying and L-dopa absorption.

  1974cited by this paper
• Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.

  1974cited by this paper
• L‐methionine

  1974cited by this paper
• Plasma levodopa and the "on-off" effect.

  1974cited by this paper
• Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's disease

  1974cited by this paper
• Cerebrospinal fluid flow and iodide 131 transport in the spinal subarachnoid space.

  1974cited by this paper
• Carbidopa in Parkinson disease and in nausea and vomiting of levodopa.

  1974cited by this paper
• “On‐off” phenomenon with levodopa therapy in parkinsonism

  1974cited by this paper
• APPRAISAL OF LONG‐TERM LEVODOPA TREATMENT OF PARKINSONISM WITH SPECIAL REFERENCE TO THERAPY LIMITING FACTORS

  1974cited by this paper
• Individualization of levodopa therapy.

  1974cited by this paper
• The "on-off" side effect of L-DOPA.

  1974cited by this paper
• Variations in the "on-off" effect.

  1974cited by this paper
• Cerebrospinal homovanillic acid and parkinsonism.

  1974cited by this paper
• Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy.

  1974cited by this paper
• Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients

  1974cited by this paper
• Some anomalies in the L-DOPA response: recent biochemical studies.

  1974cited by this paper
• Free and conjugated dopamine in plasma during levodopa therapy

  1974cited by this paper
• Variations in the "on-off" phenomenon.

  1974cited by this paper
• EFFICACY OF AND POSSIBLE DIFFERENCES IN TOLERANCE TO L‐DOPA TABLETS WITH DIFFERENT RATES OF RELEASE OF THE ACTIVE SUBSTANCE

  1974cited by this paper
• Inhibition of DOPA accumulation by rat brain at critical L-DOPA circulating concentrations.

  1974cited by this paper
• Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.

  1973cited by this paper
• Plasma concentration of levodopa in patients with Parkinson's disease.

  1973cited by this paper
• DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.

  1973cited by this paper
• An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy

  1973cited by this paper
• Behavioral effects of l-Dopa in schizophrenic patients

  1973cited by this paper
• “On-Off” Phenomena Related to High Plasma Levodopa

  1973cited by this paper
• Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.

  1973cited by this paper
• Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.

  1973cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Effect of Pyridoxine on Levodopa Metabolism in Normal and Parkinsonian Subjects

  1973cited by this paper
• Sustained-release levodopa.

  1973cited by this paper
• Lithium and levodopa in parkinsonism.

  1973cited by this paper
• Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism.

  1973cited by this paper
• Modification of levodopa effect by systemic decarboxylase inhibition.

  1973cited by this paper
• Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons

  1973cited by this paper
• Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease

  1973cited by this paper
• Sulphate Conjugation and L-Dopa Treatment of Parkinsonian Patients

  1973cited by this paper
• Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.

  1973cited by this paper
• Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.

  1973cited by this paper
• Value of plasma-dopa determinations in the management of Parkinson's disease.

  1973cited by this paper
• Catecholamine metabolism during oral administration of levodopa.

  1972cited by this paper
• Biochemical investigations in patients with Parkinson's disease treated with L‐dopa

  1972cited by this paper
• Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.

  1972cited by this paper
• The probenecid test in Parkinson's disease.

  1972cited by this paper
• [Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease].

  1972cited by this paper
• Diphenidol for levodopa induced nausea and vomiting.

  1972cited by this paper
• Cardiovascular effects of anemia.

  1972cited by this paper
• Pyridoxine and levodopa in the treatment of Parkinsonism.

  1972cited by this paper
• Pyridoxine, DOPA, and Parkinsonism.

  1972cited by this paper
• Treatment failures with levodopa in parkinsonism

  1972cited by this paper
• Peripheral aromatic l‐amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of l‐2‐14C‐dopa

  1972cited by this paper
• Observations on patients with Parkinson's disease treated with L-dopa. I. Trial and evaluation of L-dopa therapy.

  1972cited by this paper
• Central monoamine metabolism in Parkinson's disease.

  1972cited by this paper
• Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.

  1972cited by this paper
• Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.

  1972cited by this paper
• Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease

  1972cited by this paper

• Impact of Food Physical Properties on Oral Drug Absorption: A Comprehensive Review

  2025cites this paper
• Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action

  2025cites this paper
• [Promoting responsible self-medication in the context of Parkinson's disease: development of a practical guide for drug-drug interactions and assessment by patients and community pharmacy professionals].

  2022cites this paper
• Total Parenteral Nutrition and Neuroleptic Malignant-Like Syndrome in Parkinson Disease.

  2020cites this paper
• Circadian rhythms and influencing factors of xerostomia among Parkinson's disease patients.

  2018cites this paper
• Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors

  2015cites this paper
• ADVERSE EVENT REPORTING FOR A FOOD EFFECT BIOAVAILABILITY STUDY OF ROXITHROMYCIN

  2014cites this paper
• Racial and socioeconomic disparities in parkinsonism.

  2011cites this paper
• Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

  2011cites this paper
• Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson’s disease

  2009influential citation
• The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.

  2009cites this paper
• Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease

  2007cites this paper
• Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

  2007cites this paper
• SEARCHING FOR A COMMON PATHOGENETIC FACTOR AND MOLECULAR MECHANISM MALATTIE NEURODEGENERATIVE ALLA RICERCA DI UN COMUNE FATTORE PATOGENETICO E MECCANISMO MOLECOLARE LECTURE ONE PRIMA LETTURA

  2006cites this paper
• Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.

  2006cites this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  2006cites this paper
• Medical management of advanced Parkinson's disease.

  2006cites this paper
• Intestinal absorption of levodopa in man

  2004cites this paper
• Subacute l-DOPA in mice: Biochemical and behavioural effects

  2004cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• The Effect of Levodopa on Swallowing in Parkinson's Disease: are There Benefits in Administration Before Meals?

  1996cites this paper
• Influence of Diet and Nutritional Status on Drug Metabolism

  1996cites this paper
• Parkinsonian medication one hour before meals improves symptomatic swallowing: A case study

  1995cites this paper
• Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes

  1993cites this paper
• Macromolecular prodrugs. II. Esters of l-dopa and α-methyldopa

  1993cites this paper
• Acute confusional states in older adults and the role of polypharmacy.

  1992cites this paper
• L‐dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria

  1991cites this paper
• Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection.

  1990cites this paper
• Theeffects offoodon drugbioavailability

  1989cites this paper
• The effects of food on drug bioavailability.

  1989cites this paper
• The Pharmacology of Levodopa in Treatment of Parkinson’s Disease: An Update

  1989cites this paper
• The influence of nutrition on the systemic availability of drugs

  1987cites this paper
• Parkinsonism—Drug Treatment: Part I

  1987cites this paper
• The influence of nutrition on the systemic availability of drugs. Part I: Drug absorption

  1987cites this paper
• Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

  1986cites this paper
• The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa

  1985cites this paper
• Clinically desirable drug interactions.

  1985cites this paper
• CHAPTER 22 – REGULATION AND FUNCTION OF PYRIDOXAL PHOSPHATE IN CNS

  1985cites this paper
• Problems in the contemporary treatment of parkinsonism.

  1985cites this paper
• Salivary secretion induced by L-DOPA in haloperidol-treated rats.

  1984cites this paper
• Problems of levodopa treatment.

  1984cites this paper
• Kinetics of l-5-hydroxytryptophan in healthy subjects.

  1982cites this paper
• The management of Parkinson's disease.

  1982cites this paper
• Effects of tetrahydroisoquinolines on dopa decarboxylase and pyridoxal kinase

  1981cites this paper
• Regulation and function of pyridoxal phosphate in CNS.

  1981cites this paper
• Studies on the mechanisms of L-dopa-induced salivary secretion.

  1981cites this paper